Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 300 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Daniel J. Lippis sold 300 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $70.61, for a total value of $21,183.00. Following the sale, the vice president now directly owns 22,863 shares in the company, valued at $1,614,356.43. This trade represents a 1.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Edwards Lifesciences Price Performance

NYSE EW traded up $1.06 on Friday, reaching $69.32. The company had a trading volume of 4,890,092 shares, compared to its average volume of 4,914,207. The firm's 50 day moving average price is $71.32 and its 200 day moving average price is $70.70. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $95.25. The stock has a market capitalization of $40.75 billion, a PE ratio of 9.95, a price-to-earnings-growth ratio of 4.82 and a beta of 1.15. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Centiva Capital LP acquired a new stake in Edwards Lifesciences during the 3rd quarter worth $295,000. Quantinno Capital Management LP lifted its holdings in shares of Edwards Lifesciences by 29.2% in the 3rd quarter. Quantinno Capital Management LP now owns 53,183 shares of the medical research company's stock valued at $3,510,000 after purchasing an additional 12,028 shares during the last quarter. Stifel Financial Corp grew its stake in Edwards Lifesciences by 11.9% during the 3rd quarter. Stifel Financial Corp now owns 232,738 shares of the medical research company's stock worth $15,358,000 after buying an additional 24,731 shares during the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in shares of Edwards Lifesciences by 65.2% in the third quarter. Kovitz Investment Group Partners LLC now owns 23,039 shares of the medical research company's stock valued at $1,520,000 after acquiring an additional 9,093 shares during the period. Finally, National Bank of Canada FI increased its holdings in shares of Edwards Lifesciences by 27.7% in the 3rd quarter. National Bank of Canada FI now owns 303,853 shares of the medical research company's stock valued at $20,051,000 after acquiring an additional 65,982 shares during the period. Institutional investors and hedge funds own 79.46% of the company's stock.

Analyst Upgrades and Downgrades

EW has been the subject of several analyst reports. Truist Financial reduced their price objective on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating for the company in a research note on Friday. Evercore ISI reduced their target price on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research note on Wednesday, February 12th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the company a "hold" rating in a research report on Thursday, February 13th. Finally, Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and a consensus price target of $78.55.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.